FindTrial
Sign In

AFM13

DRUG5 trials

Sponsors

University of Cologne, Affimed GmbH, Ahmed Sawas

Conditions

Hodgkin LymphomaLymphoma, T-Cell, CutaneousPeripheral T Cell LymphomaRelapsed or Refractory Hodgkin LymphomaTransformed Mycosis Fungoides

Phase 1

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
CompletedNCT02665650
Affimed GmbHHodgkin Lymphoma
Start: 2016-05-31End: 2019-03-31Updated: 2019-05-16
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
CompletedNCT03192202
Ahmed SawasLymphoma, T-Cell, Cutaneous
Start: 2017-07-17End: 2020-04-01Updated: 2023-07-20

Phase 2

GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
CompletedNCT02321592
University of CologneHodgkin Lymphoma
Start: 2015-05-31End: 2020-07-31Updated: 2020-11-13
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
CompletedNCT04101331
Affimed GmbHPeripheral T Cell Lymphoma, Transformed Mycosis Fungoides
Start: 2019-11-13End: 2024-01-11Updated: 2024-11-05
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
TerminatedNCT05883449
Affimed GmbHPeripheral T Cell Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Start: 2023-10-10End: 2025-06-13Updated: 2025-08-20

Related Papers

Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203).
Journal of Clinical Oncology2025-05-281 citations
Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study
Blood2024-11-053 citations
AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)
Blood2023-11-0211 citations
P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY
HemaSphere2023-08-013 citations
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (<i>R</i>/<i>R</i>) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY
Hematological Oncology2023-06-01
Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)
Cancer Research2023-04-1414 citations
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial
Leukemia & lymphoma/Leukemia and lymphoma2022-07-0352 citations
Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager (ICE®) AFM13 for the Treatment of CD30 + Malignancies
Blood2021-11-051 citations
894 The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing
Regular and Young Investigator Award Abstracts2021-11-01
AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Final Results of an Open-Label, Randomized, Multicenter Phase II Trial
Blood2020-11-048 citations
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Blood2020-07-31145 citations
A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.
Journal of Clinical Oncology2020-05-209 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Lenolidamide and IL-15 enhance natural killer cell-mediated immunity and augments the anti-tumor effect of an anti-CD30/CD16A bispecific antibody against Hodgkin’s lymphoma B-cells
The Journal of Immunology2019-05-01
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
Blood2018-11-2916 citations